Photo from wikipedia
Direct-acting antivirals (DAAs) are novel drugs that have changed the treatment landscape of hepatitis C. Novel brand-name medications, like DAAs, are highly priced, bringing financial burden to patients and health… Click to show full abstract
Direct-acting antivirals (DAAs) are novel drugs that have changed the treatment landscape of hepatitis C. Novel brand-name medications, like DAAs, are highly priced, bringing financial burden to patients and health systems.1 Physicians’ uptake after approval is key to commercial success of these medications, with uptake associated with peer influence and their relationship with pharmaceutical marketing.2,3 However, little is known about patterns of pharmaceutical marketing for DAAs. Thus, in this study, we aim to fill this knowledge gap.
Journal Title: Annals of Pharmacotherapy
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!